secwatch.observer — SEC 8-K summary
======================================

Issuer:     ABEONA THERAPEUTICS INC. (ABEO)
CIK:        0000318306
Form:       8-K
Filed at:   2024-10-29T23:59:59+00:00
Accession:  0001493152-24-042775
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Abeona Therapeutics resubmits BLA for pz-cel gene therapy for RDEB to FDA
-------------------------------------------------------------------------

- Resubmitted Biologics License Application (BLA) for pz-cel to FDA for recessive dystrophic epidermolysis bullosa (RDEB).
- Resubmission addresses all Chemistry Manufacturing and Controls (CMC) items from April 2024 Complete Response Letter.
- No new clinical trials or data requested; prior CRL had no deficiencies in safety or efficacy.
- FDA expected to set new PDUFA target action date; review period is 2 or 6 months based on classification.
- Pz-cel holds Regenerative Medicine Advanced Therapy, Breakthrough, Orphan, and Rare Pediatric Disease designations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/318306/000149315224042775/0001493152-24-042775-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/318306/000149315224042775/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-042775

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer